# Iteria Biopharma

Source: https://onco.cc/companies/iteria-biopharma/  
OnCo record `iteria-biopharma` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

Iteria Biopharma is a Galician company designing new small-molecule medicines for cancer. Its first, ITR-251, is aimed at prostate cancer that has spread and stopped responding to hormone therapy, and is due to start its first human trial.

## Summary

Iteria Biopharma, S.L. is a precision oncology drug discovery company based in Touro, A Coruña, in Galicia, Spain. It presented itself as a new Galician biotech in December 2024, founded by the chemistry company GalChimia (Carme Pampín), Julio Castro of Palobiofarma, and Ramon Bosser, who is chief executive; it was set up to take over GalChimia's MAOPROST project. It designs first-in-class new chemical entities. Its lead, ITR-251, is for metastatic castration-resistant prostate cancer, and two early research programmes address pancreatic, colorectal and lung cancer. A phase 1/1b study (NCT07870096) is registered to test ITR-251 first in advanced solid tumours and then in metastatic castration-resistant prostate cancer together with androgen receptor pathway inhibitors. In April 2026 it closed a EUR 5 million seed round led by Inveready through Inveready Biotech IV, with Xunta de Galicia co-investing through Xesgalicia alongside existing investors and the founders.

## Fields

- Kind: Company
- Last checked: 2026-10-29
- Also known as: ITERIA BIOPHARMA, S.L.
- HQ: Touro, Galicia
- Type: biotech
- Website: https://iteriabiopharma.com/

## Notes

- Founding year not stated; the company announced itself in a release datelined 3 December 2024. ITR-251's molecular target is not disclosed, so no target is linked. No technology is linked: ITR-251's mechanism is not disclosed, and the registered trial combines it with androgen receptor pathway inhibitors without describing it as one. ClinicalTrials.gov gives a start in October 2026, while the seed release said the first phase 1 trial would start in early 2027. Parts of the company website still carry template placeholder text.

## Sources

- Official website: https://iteriabiopharma.com/
- Company launch announcement, December 2024: https://iteriabiopharma.com/2024/12/04/iteria-biopharma-the-new-galician-biotech-focused-on-the-discovery-of-precision-drugs-for-cancer-treatment/
- Seed round release, April 2026: https://iteriabiopharma.com/2026/04/16/iteria-biopharma-closes-a-e5m-seed-round/
- ClinicalTrials.gov: ITR-251 phase 1/1b (NCT07870096): https://clinicaltrials.gov/study/NCT07870096

## Connected records

- cancers: [Colorectal cancer](https://onco.cc/cancers/colorectal/), [Metastatic castration-resistant prostate cancer](https://onco.cc/cancers/prostate-mcrpc/), [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)

---
JSON: https://onco.cc/api/v1/entities/iteria-biopharma.json